Key Highlights
- EUR 1.3 billion of third-quarter revenue, down from EUR 1.5 billion a year earlier, mainly on lower expected Demand for the COVID-19 vaccine, the company said on November 3, 2026.
- EUR 613 million of the quarter's Revenue was recognized from the BMS Partnership on the bispecific antibody candidate pumitamig.
- EUR 16.2 billion of cash equivalents and security investments at the end of the third quarter, plus about 5 million shares repurchased since June.
- Updated 2026 revenue guidance of EUR 1.7 to 1.9 billion, with the midpoint raised and adjusted R&D guidance unchanged at EUR 2.0 to 2.3 billion.
Vaccine Decline Masked by BMS Partnership Revenue
BioNTech (NASDAQ:BNTX) discussed third-quarter 2026 results on a call on November 3, 2026. Revenue was EUR 1.3 billion against EUR 1.5 billion in the prior-year quarter, which the company attributed mainly to anticipated lower market demand for its COVID-19 vaccine. Revenue of EUR 613 million came from its strategic partnership with BMS on co-developing and co-commercializing pumitamig, so a large part of the quarter reflects partnership accounting, not product sales. Nine-month revenue was EUR 1.5 billion versus EUR 2 billion. Management raised the midpoint of 2026 revenue guidance, which now stands at EUR 1.7 to 1.9 billion.
Spending Rises as the Oncology Pipeline Expands
Adjusted R&D expenses rose to EUR 579 million from EUR 479 million, reflecting Investment in immuno-oncology and antibody-drug conjugate programs. On an IFRS basis R&D was EUR 748 million, because the additional EUR 169 million included Impairment losses on intangible assets outside its strategic focus. SG&A was EUR 179 million versus EUR 149 million on pre-launch work, commercial build-up and an ERP upgrade, partly offset by savings from pipeline prioritization. Nine-month adjusted R&D reached EUR 1.6 billion and adjusted SG&A EUR 527 million, up from EUR 407 million. Full-year guidance for adjusted R&D of EUR 2.0 to 2.3 billion and SG&A of EUR 700 to 800 million is unchanged. With EUR 16.2 billion in cash and securities, the company says it can pursue its goal of becoming a multi-product company by 2030.
Mixed Trial News, CEO Handover and Year-End Readout
Clinical news was mixed. Gotistobart showed median overall survival of 18.5 months versus 10 months for docetaxel in the non-pivotal part of a squamous lung cancer trial, a hazard ratio of 0.56, and a first interim analysis in the pivotal part is expected before year-end. The AHEAD-MERIT trial missed its first primary endpoint of progression-free survival but continues toward overall survival. The T-Pam trial met its progression-free survival goal with what the company called a modest improvement and a higher interstitial lung disease rate, and a colorectal trial of autogene cevumeran was discontinued. Uğur Şahin gave his last earnings call, with Guido Oelkers taking over as CEO by February 1 at the latest. The company also started six phase III trials this year. Early response rates came from small groups of patients and may not hold in larger trials.
Where Things Stand
Revenue fell because Vaccine demand declined, and the BMS payment softened the drop rather than reversing it. BioNTech (NASDAQ:BNTX) still raised the midpoint of 2026 revenue guidance and holds EUR 16.2 billion in cash and securities, but spending is rising and several trial results were mixed. The gotistobart interim analysis before year-end, the CEO handover and any decision on a T-Pam submission are the next markers.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...